Featured Articles
-
State Of The Orphan Space
3/1/2024
Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing practices.
-
NORD Expands Advocacy And Support For Rare Disease Patients, And Industry
2/29/2024
NORD's president and CEO, Peter Saltonstall, offers details on the organization's current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.
-
Companies To Watch: Antiva Biosciences
2/27/2024
Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
-
The Industry’s Positive Outlook For ADCs In 2024
2/26/2024
Check out the results of DeciBio's Antibody-Drug Conjugates 2024 Industry Survey, which predict another bullish year for the growing modality.
-
The Good And Bad Of Copromotion
2/26/2024
Are two minds, or companies, better than one for drug commercialization? It depends on the details, says Eisai's Paul Hawthorne.
-
“Ruthless” Resourcing Rules For CEOs
2/22/2024
Former president and CEO of Albireo Pharma, Ron Cooper, describes six 'Ruthless Resourcing Rules' to help CEOs use hiring and talent management for a competitive advantage.
-
Understanding And Navigating Diverse Regulatory Environments
2/21/2024
Drug developers aspire to treat patients globally, but navigating diverse regulatory structures around the world gets tricky. These consultants offer a primer on the regulatory bodies of the world.
-
No Playbook For Leqembi: Eisai’s Long Game In Alzheimer’s Disease
2/16/2024
Paul Hawthorne, Eisai's EVP, purpose and chief business officer, offers insight into building a market for Leqembi, Eisai's pricing and commercial strategy, and the challenges and opportunities in Alzheimer's disease.
-
In The UK, Location Is Key To Survival For Life Sciences Startups
2/14/2024
Startup biotech and pharmaceutical companies can benefit from basing themselves in locations where ‘chance’ meetings with decision makers and potential collaborators are more likely to occur. The benefits of proximity between startups and Big Pharma go both ways.
-
How AI Is Helping Drug Developers Help Rare Disease Patients
2/14/2024
BioCryst's chief R&D officer provides examples of how AI and machine learning tools are being used to improve rare disease drug discovery and development.